Diagnostic value of reduced field-of-view diffusion-weighted imaging for prostate cancer. [J]. Journal of Southwest Medical University 44(6):650-653(2021)
DOI:
Diagnostic value of reduced field-of-view diffusion-weighted imaging for prostate cancer. [J]. Journal of Southwest Medical University 44(6):650-653(2021) DOI: 10.3969/j.issn.2096-3351.2021.06.011.
Diagnostic value of reduced field-of-view diffusion-weighted imaging for prostate cancer
Objective To investigate the value of reduced field-of-view diffusion-weighted imaging (r-FOV DWI) in diagnosing prostate cancer. Methods We retrospectively selected 83 patients with a pathological diagnosis of prostate cancer. All the patients had undergone conventional-FOV DWI(c-FOV DWI)and r-FOV DWI before surgery. Two doctors scored the images on a subjective basis and measured the apparent diffusion coefficient(ADC) of the lesions. MRI data
prostate-specific antigen results
and pathological results were analyzed. Results The sub⁃jective image quality of r-FOV DWI was significantly higher than that of c-FOV DWI(P<0.05). The ADC value of lesions measured on r-FOV DWI was lower than that on c-FOV DWI
but there was no significant difference(P>0.001). When ADC was 1.074 × 10-3 s/mm2 in the c-FOV DWI group
the sensitivity and specificity of diagnosis were 81% and 63%
respectively. When ADC was 0.993×10-3 s/mm2 in the r-FOV DWI group
the sensitivity and specificity were 79% and 75%
respectively. The areas under the receiver operating characteristic curves of the two methods were 0.813 and 0.825
respectively
indicating comparable diagnostic performance for prostate cancer(P>0.05). Conclusion r-FOV DWI has better image quality than c-FOV DWI
and can serve as a more effective ap⁃proach to the diagnosis of prostate cancer.
关键词
MRI小视野扩散加权成像前列腺癌
Keywords
MRIReduced field-of-view diffusion-weighted imagingProstate cancer
Research progress of targeted radionuclide imaging agents for prostate cancer
Progress in the first clinical application of radiopharmaceuticals in oncology and neurology and prospects for the development of medical isotopes in China
Related Author
XIE Qiang
刘会攀
杨宇川
陈
跃
Related Institution
Department of Nuclear Medicine,The First Affiliated Hospital University of Science and Technology of China
Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University
Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province
Academician (Expert) Workstation of Sichuan Province
Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics